92 127

Cited 0 times in

A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane

DC FieldValueLanguage
dc.contributor.author라선영-
dc.contributor.author정현철-
dc.date.accessioned2016-05-16T11:08:02Z-
dc.date.available2016-05-16T11:08:02Z-
dc.date.issued2002-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/143862-
dc.description.abstractPurpose: We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine antimetabolite, in patients, who had previously failed anthracycline and taxane-based chemotherapy for the treatment of metastatic breast cancer. Materials and Methods: Twenty-one patients with metastatic breast cancer, which was unresponsive to previous chemotherapy, were entered into this study. Gemcitabine was administered at 850 mg/m2, as a 60- minute intravenous infusion on days 1, 8 and 15. This regimen was repeated every 28 days with G-CSF support, but without dose reduction. Results: Objective responses were seen in 6 of the 20 patients who were able to be evaluated (1 complete response and 5 partial responses), with an objective response rate of 30%. The median time to progression was 5 (1∼20) months, and the median overall survival duration was 11 (2∼21) months. The actual dose intensity was 566.7 mg/m2/wk (range; 340∼637.5 mg/m2/wk) and the relative dose intensity was 0.89 (range; 0.40∼1.00). Toxicity was mainly hematological. Toxicities included: grade 3 neutropenia in 20% and anemia in 5%. Grades 3 and 4 thrombocytopenia occurred in 15% of the patients. Conclusion: Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen.-
dc.description.statementOfResponsibilityopen-
dc.format.extent274~279-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleA phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorChul Kim-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorYong Tae Kim-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorWoo Ick Jang-
dc.contributor.googleauthorGwi Eon Kim-
dc.contributor.googleauthorHyun Cheol Chung-
dc.identifier.doi10.4143/crt.2002.34.4.274-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03773-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid26680875-
dc.subject.keywordChemotherapy-
dc.subject.keywordGemcitabine-
dc.subject.keywordMetastatic breast neoplasm-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsfree-
dc.citation.volume34-
dc.citation.number4-
dc.citation.startPage274-
dc.citation.endPage279-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.34(4) : 274-279, 2002-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.